Suppr超能文献

诱导化疗在喉保留策略中仍有作用吗?加泰罗尼亚肿瘤研究所对III期喉癌的治疗经验。

Does induction chemotherapy still have a role in larynx preservation strategies? The experience of Institut Catala d'Oncologia in stage III larynx carcinoma.

作者信息

Majem Margarita, Mesia Ricard, Mañós Manel, Gomez Joaquin, Galiana Ramon, Cardenal Felipe, Juan Amparo, Montes Ana, Perez Francisco Javier, Nogues Julio, Llluch Josep Ramon Germa

机构信息

Department of Medical Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.

出版信息

Laryngoscope. 2006 Sep;116(9):1651-6. doi: 10.1097/01.mlg.0000231736.08477.47.

Abstract

BACKGROUND

Radiotherapy with concurrent cisplatin is the standard alternative to total laryngectomy for patients with locally advanced laryngeal cancer. The value of induction chemotherapy in larynx-preservation therapies remains unknown. Hyperfractionation radiotherapy might improve disease-free survival.

METHODS

From August 1993 to August 2004, 71 patients with T3N0-1 larynx tumors and eligible for total laryngectomy received induction chemotherapy with three cycles of cisplatin plus fluorouracil. Clinical tumor response was assessed by indirect laryngoscopy and computed tomography scan. Patients with complete response received hyperfractionation radiotherapy, whereas those without complete response were proposed for total laryngectomy.

RESULTS

A total of 71 consecutive patients were included. Thirty-three patients achieved complete response to induction chemotherapy (46.5%), four of them presented a tumor relapse, and all underwent salvage surgery. Seventy-six percent of surviving patients preserved a functional larynx. Despite not achieving complete response, 15 patients refused total laryngectomy and received hyperfractionation radiotherapy. Seven patients presented a tumor relapse and salvage surgery was performed in three of them. Fifty percent of surviving patients preserved a functional larynx. Twenty-two patients without complete response underwent total laryngectomy; three of them presented a tumor relapse but none could be rescued. With a median follow up of 68 months, 5 five-year overall survival, 5-year disease-free survival, and 5-year larynx function preservation survival rates were 68% (confidence interval [CI], 57-80), 75% (CI, 64-87), and 42% (CI, 29-54), respectively. No differences in overall survival were observed between groups. Five-year disease-free survival of patients without complete response who received hyperfractionation radiotherapy was significantly lower than that of the other two groups (P < .02). Ten patients with larynx preservation and no tumor relapse had chronic toxicity that caused the loss of larynx function: seven patients required permanent tracheotomy, two died from pneumonia, and one patient died as a result of a laryngeal necrosis.

CONCLUSIONS

Patients with complete response to induction chemotherapy in laryngeal carcinoma have a high probability of cure after hyperfractionation radiotherapy. However, hyperfractionation radiotherapy induces a high degree of toxicity that reduces the laryngeal function preservation rate and may jeopardize overall survival.

摘要

背景

对于局部晚期喉癌患者,同步顺铂放疗是全喉切除术的标准替代方案。诱导化疗在喉保留治疗中的价值尚不清楚。超分割放疗可能会提高无病生存率。

方法

从1993年8月至2004年8月,71例T3N0 - 1期喉部肿瘤且适合全喉切除术的患者接受了三个周期顺铂加氟尿嘧啶的诱导化疗。通过间接喉镜检查和计算机断层扫描评估临床肿瘤反应。完全缓解的患者接受超分割放疗,而未完全缓解的患者则建议行全喉切除术。

结果

共纳入71例连续患者。33例患者对诱导化疗完全缓解(46.5%),其中4例出现肿瘤复发,均接受了挽救性手术。76%的存活患者保留了功能性喉部。尽管未完全缓解,15例患者拒绝全喉切除术并接受了超分割放疗。7例患者出现肿瘤复发,其中3例接受了挽救性手术。50%的存活患者保留了功能性喉部。22例未完全缓解的患者接受了全喉切除术;其中3例出现肿瘤复发,但均无法挽救。中位随访68个月,5年总生存率、5年无病生存率和5年喉功能保留生存率分别为68%(置信区间[CI],57 - 80)、75%(CI,64 - 87)和42%(CI,29 - 54)。各组间总生存率无差异。接受超分割放疗的未完全缓解患者的5年无病生存率显著低于其他两组(P <.02)。10例保留喉部且无肿瘤复发的患者有导致喉功能丧失的慢性毒性:7例患者需要永久性气管切开,2例死于肺炎,1例因喉坏死死亡。

结论

喉癌诱导化疗完全缓解的患者在超分割放疗后有很高的治愈概率。然而,超分割放疗会诱导高度毒性,降低喉功能保留率,并可能危及总生存率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验